A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma Journal Article
| Authors: | Batlevi, C. L.; Crump, M.; Andreadis, C.; Rizzieri, D.; Assouline, S. E.; Fox, S.; van der Jagt, R. H. C.; Copeland, A.; Potvin, D.; Chao, R.; Younes, A. |
| Article Title: | A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma |
| Abstract: | Deregulation of histone deacetylase (HDAC) is important in the pathogenesis of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Mocetinostat, an isotype-selective HDAC inhibitor, induces accumulation of acetylated histones, cell cycle arrest and apoptosis in several cancers. This phase 2 study evaluated mocetinostat in patients with relapsed/refractory (R/R) DLBCL and FL. Seventy-two patients received mocetinostat (starting doses: 70–110 mg TIW, 4-week cycles). The best overall response rate (95% CI) was 18·9% (7·2, 32·2) for the DLBCL cohort (n = 41), and 11·5% (1·7, 20·7) for the FL cohort (n = 31). Responses were durable (≥90 days in 7 of 10 responses). Overall, 54·1% and 73·1% of patients derived clinical benefit (response or stable disease) from mocetinostat in the DLBCL and FL cohorts, respectively. Progression-free survival ranged from 1·8 to 22·8 months and 11·8 to 26·3 months in responders with DLBCL and FL, respectively. The most frequent treatment-related adverse events were fatigue (75·0%), nausea (69·4%) and diarrhoea (61·1%). Although mocetinostat had limited single-agent activity in R/R DLBCL and FL, patients with clinical benefit had long-term disease control. The safety profile was acceptable. This drug class warrants further investigation, including identifying patients more likely to respond to this agent, or in combination with other agents. © 2017 John Wiley & Sons Ltd |
| Keywords: | follicular lymphoma; histone deacetylase; diffuse large b-cell lymphoma; mocetinostat; phase 2 study |
| Journal Title: | British Journal of Haematology |
| Volume: | 178 |
| Issue: | 3 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2017-08-01 |
| Start Page: | 434 |
| End Page: | 441 |
| Language: | English |
| DOI: | 10.1111/bjh.14698 |
| PROVIDER: | scopus |
| PUBMED: | 28440559 |
| PMCID: | PMC5576135 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 August 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work